Valuation: Incyte Corporation

Market Cap 22.73B 19.89B 18.35B 17.14B 32.29B 2,148B 32.99B 221B 85.21B 1,060B 85.34B 83.47B 3,680B P/E 2026 *
16.8x
P/E 2027 * 14.4x
Enterprise Value 17.72B 15.52B 14.31B 13.37B 25.18B 1,676B 25.73B 172B 66.46B 826B 66.56B 65.1B 2,870B EV / Sales 2026 *
3.14x
EV / Sales 2027 * 2.55x
Free-Float
98.11%
Yield 2026 *
-
Yield 2027 * -
1 day+0.80%
1 week+16.74%
Current month+18.52%
1 month+17.60%
3 months+26.98%
6 months+14.53%
Current year+16.09%
1 week 103.07
Extreme 103.07
115.56
1 month 92.18
Extreme 92.18
115.56
Current year 89.25
Extreme 89.25
115.56
1 year 66.83
Extreme 66.83
115.56
3 years 50.27
Extreme 50.27
115.56
5 years 50.27
Extreme 50.27
115.56
10 years 50.27
Extreme 50.27
153.15
Manager TitleAgeSince
Chief Executive Officer 58 25/06/2025
Director of Finance/CFO 57 03/05/2026
President 62 04/06/2023
Director TitleAgeSince
Chairman 59 25/06/2025
Director/Board Member 72 19/01/2015
Director/Board Member 64 19/01/2015
Date Insider Type Main position Quantity % Market Cap.
06-07Free

Director

7,753 0.0039%
06-07Other

Director

0 0%
06-07Free

Director

7,753 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
+0.80%+16.74%+67.71%+88.12% 22.73B
-0.17%+3.59%+21.27%-9.75% 64.39B
+1.93%+5.53%+54.82%+230.70% 56.12B
+7.82%+44.80%+44.80%+44.80% 40.54B
+0.45%-0.80%-50.76%-58.54% 37.98B
+0.28%+10.20%+71.82%-23.73% 31.89B
+3.61%+8.97%+156.63%-43.33% 26.69B
+6.52%+5.12%+3.49%+174.61% 16.66B
-0.77%+5.09%+62.54%+121.98% 16.6B
+2.52%+8.66%+60.52%+299.83% 13.76B
Average +1.91%+6.13%+49.28%+82.47% 32.74B
Weighted average by Cap. +1.78%+5.87%+43.60%+64.33%

Financials

2026 *2027 *
Net sales 5.64B 4.94B 4.56B 4.26B 8.02B 533B 8.19B 54.8B 21.16B 263B 21.19B 20.72B 914B 6.23B 5.45B 5.03B 4.7B 8.85B 589B 9.04B 60.48B 23.35B 290B 23.38B 22.87B 1,008B
Net income 1.41B 1.24B 1.14B 1.07B 2.01B 134B 2.05B 13.73B 5.3B 65.92B 5.31B 5.19B 229B 1.66B 1.45B 1.34B 1.25B 2.35B 157B 2.4B 16.08B 6.21B 77.21B 6.22B 6.08B 268B
Net Debt -5B -4.38B -4.04B -3.77B -7.1B -473B -7.26B -48.56B -18.75B -233B -18.78B -18.37B -810B -6.86B -6B -5.54B -5.17B -9.74B -648B -9.96B -66.61B -25.72B -320B -25.76B -25.19B -1,111B
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
29/06/26 US$114.74 +0.87% 1,505,870
26/06/26 US$113.75 +5.78% 3,795,266
25/06/26 US$107.53 -0.86% 1,832,481
24/06/26 US$108.46 +3.89% 1,963,908
23/06/26 US$104.40 +0.71% 1,670,984
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
113.75USD
Average target price
110.70USD
Spread / Average Target
-2.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INCY Stock